Kuzmanović Elabjer Biljana, Bušić Mladen, Pleše Andrej, Bjeloš Mirjana, Miletić Daliborka, Vukojević Nenad
Faculty of Dental Medicine and Health Care Osijek, University Josip Juraj Strossmayer in Osijek, Osijek, Croatia.
Faculty of Medicine Osijek, University Josip Juraj Strossmayer in Osijek, Osijek, Croatia.
Ocul Oncol Pathol. 2021 Jun;7(3):224-232. doi: 10.1159/000512030. Epub 2021 Feb 15.
Ultrasound biomicroscopy (UBM) is the only widely used method for the evaluation of anterior uveal melanoma (AUM).
Documentation of regression of AUM treated with ruthenium-106 (Ru-106) plaque types CCB and CCC using UBM.
This single institution-based retrospective case series involved 10 Caucasian patients with AUM followed after brachytherapy with UBM from January 2014 until February 2019. The largest prominence of the tumor perpendicular to the sclera or the cornea (including scleral/corneal thickness) () and the largest basal dimension () were measured in millimeters with UBM for all patients prior to the brachytherapy and at 4-month interval follow-up. Tumor regression was calculated as a percentage of decrease in the initial and values.
The study involved 10 patients with a mean age of 64.4 years (yr) (range 46-80 yr). ranged from 1.82 to 5.5 mm (median 2.99 mm) and from 2.32 to 12.38 mm (median 4.18 mm). The apical radiation dose in all patients was 100 Gy. The median follow-up was 42.02 months. Regression for was 21.11 ± 13.66%, 31.09 ± 14.66%, and 34.92 ± 19.86% at 1st, 2nd, and 3rd year of the follow-up, respectively, while for it was 21.58 ± 16.05%, 28.98 ± 17.71%, and 32.06 ± 18.96%, respectively. Tumor recurrence was documented in 2/10 patients.
The major regression of AUM, treated with Ru-106 plaque types CCB and CCC, was documented in the first 2 years after brachytherapy in our study group. In the following years, only minimal regression was documented that warns of the need for close monitoring and active search for local recurrences.
超声生物显微镜检查（UBM）是目前广泛用于评估前葡萄膜黑色素瘤（AUM）的唯一方法。
使用UBM记录接受CCB和CCC型钌-106（Ru-106）斑块治疗的AUM的消退情况。
本单机构回顾性病例系列研究纳入了10例白种人AUM患者，于2014年1月至2019年2月接受近距离放射治疗后，采用UBM进行随访。在近距离放射治疗前及随访期间，每隔4个月用UBM测量所有患者肿瘤垂直于巩膜或角膜的最大突出度（包括巩膜/角膜厚度）（）和最大基底尺寸（），以毫米为单位。肿瘤消退以初始和值下降的百分比计算。
该研究纳入10例患者，平均年龄64.4岁（范围46 - 80岁）。范围为1.82至5.5毫米（中位数2.99毫米），范围为2.32至12.38毫米（中位数4.18毫米）。所有患者的顶端放射剂量为100 Gy。中位随访时间为42.02个月。随访第1年、第2年和第3年时，的消退率分别为21.11±13.66%、31.09±14.66%和34.92±19.86%，而的消退率分别为21.58±16.05%、28.98±17.71%和32.06±18.96%。10例患者中有2例记录到肿瘤复发。
在我们的研究组中，接受CCB和CCC型Ru-106斑块治疗的AUM在近距离放射治疗后的前2年出现了主要消退。在接下来的几年中，仅记录到极小的消退，这提示需要密切监测并积极寻找局部复发情况。
